Aurinia (Formerly Known as Isotechnika Pharma Inc.)
5120 - 75th Street
264 articles with Aurinia (Formerly Known as Isotechnika Pharma Inc.)
7/19/2019Pharma and biotech companies from across the globe expand their leadership teams and boards.
Aurinia Pharmaceuticals Inc. announced the appointments of Mr. Max Donley as Executive Vice President of Internal Operations and Strategy and Dr. Glenn Schulman as Senior Vice President of Corporate Communications and Investor Relations.
Aurinia Pharmaceuticals Inc. is pleased to announce that shareholders of the Company elected all eight of the Company’s highly qualified director nominees at the Company’s Annual General Meeting held on June 26, 2019.
Aurinia Pharmaceuticals Inc. reminded shareholders to vote in advance of the proxy voting deadline of 10:00 AM Mountain Time on Monday, June 24, 2019.
ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
Shareholders Urged to Vote Their GREEN Proxy or GREEN VIF to Strengthen Board with Three New, Highly Qualified Independent Nominees
Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the following upcoming investor conferences
Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET) in New York, NY.
Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes.
Aurinia Pharmaceuticals Inc. announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board.
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
Dr. Richard M. Glickman to retire from executive and board roles and remain an advisor to the Company for one year
Aurinia Pharmaceuticals Inc. reported its financial results for the fourth quarter and year ended December 31, 2018.
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. announced a host of activities, including an initiative with The National Kidney Foundation, designed to raise awareness for kidney disease.
Aurinia Pharmaceuticals Inc. announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis
Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES
Aurinia Pharmaceuticals Inc., announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST
Aurinia Pharmaceuticals Inc. today announced that it has entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to US$30,000,000.
Aurinia Pharmaceuticals Inc. today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule